Insufficient Antiretroviral Therapy in Pregnancy: Missed Opportunities for Prevention of Mother-To-Child Transmission of HIV in Europe

Abstract

Background

Although mother-to-child transmission (MTCT) rates are at an all-time low in Western Europe, potentially preventable transmissions continue to occur. Duration of antenatal combination antiretroviral therapy (ART) is strongly associated with MTCT risk.

Methods

Data on pregnant HIV-infected women enrolled in the Western and Central European sites of the European Collaborative Study between January 2000 and July 2009 were analysed. The proportion of women receiving no antenatal ART or 1–13 days of treatment was investigated, and associated factors explored using logistic regression models.

Results

Of 2,148 women, 142 (7%) received no antenatal ART, decreasing from 8% in 2000–2003 to 5% in 2004– 2009 (χ²=8.73; P<0.01). A further 41 (2%) received 1–13 days of ART. One-third (64/171) of women with ‘insufficient’ (0 or 1–13 days) antenatal ART had a late HIV diagnosis (in the third trimester or intrapartum), but half (85/171) were diagnosed before conception. Pre-term delivery <34 weeks was associated with receipt of no and 1–13 days antenatal ART (adjusted odds ratios [ORs] 2.9 [P<0.01] and 4.5 [P<0.01], respectively). History of injecting drug use was associated with an increased risk of no ART (adjusted OR 2.9; P<0.01) and severe symptomatic HIV disease with a decreased risk (adjusted OR 0.2; P<0.01). MTCT rates were 1.1% (15/1,318) among women with ≥14 days antenatal ART and 7.4% (10/136) among those with insufficient ART.

Conclusions

Over the last 10 years, around one in 11 women in this study received insufficient antenatal ART, accounting for 40% of MTCTs. One-half of these women were diagnosed before conception, suggesting disengagement from care.

References

Warszawski

, Tubiana

, Le Chenadec

Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22: 289–299.

Townsend

C.L.

, Cortina-Borja

, Peckham

C.S.

, de Ruiter

, Lyall

, Tookey

P.A.

Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008; 22: 973–981.

European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006; 20: 1419–1427.

National Study of HIV in Pregnancy and Childhood, NHS Audit Information Analysis Unit, Children's HIV Association. Perinatal transmission of HIV in England 2002–2005. London, UK: Audit Information and Analysis Unit for London, Kent, Surrey and Sussex, Essex, Beds & Herts 2007.

Deblonde

, Claeys

, Temmerman

Antenatal HIV screening in Europe: a review of policies. Eur J Public Health 2007; 17: 414–418.

Townsend

C.L.

, Cortina-Borja

, Peckham

C.S.

, Tookey

P.A.

Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990–2006. BJOG 2008; 115: 1078–1086.

Keiser

, Gayet-Ageron

, Rudin

Antiretroviral treatment during pregnancy. AIDS 2008; 22: 2323–2330.

Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. (Updated 24 May 2010. Accessed 29 June 2011.) Available from http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.

de Ruiter

, Mercey

, Anderson

British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9: 452–502.

10.

Townsend

C.L.

, Cortina-Borja

, Peckham

C.S.

, Tookey

P.A.

Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019–1026.

11.

Thorne

, Newell

M.L.

Safety of agents used to prevent mother-to-child transmission of HIV: Is there any cause for concern?

Drug Saf 2007; 30: 203–213.

12.

Thorne

, Patel

, Newell

M.L.

Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18: 2337–2339.

13.

European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380–387.

14.

European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 458–465.

15.

Jasseron

, Mandelbrot

, Tubiana

Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women?

AIDS 2008; 22: 1503–1511.

16.

Cooper

E.R.

, Charurat

, Mofenson

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484–494.

17.

European Collaborative Study. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44: 1647–1656.

18.

Landes

, Newell

M.L.

, Barlow

Hepatitis B or hepatitis C coinfection in HIV-infected pregnant women in Europe. HIV Med 2008; 9: 526–534.

19.

von Linstow

M.L.

, Rosenfeldt

, Lebech

A.M.

Prevention of mother-to-child transmission of HIV in Denmark, 1994–2008. HIV Med 2010; 11: 448–456.

20.

World Health Organisation. Antiretroviral drugs for treating pregnant women and preventing HIV infection in their infants: Recommendations for a public health approach. 2010 version. Geneva, Switzerland: World Health Organisation; 2010.

21.

European Collaborative Study. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med 2010; 11: 368–378.

22.

Royal College of Obstetricians and Gynaecologists. Medical terms explained. (Updated April 2011. Accessed July 2011.) Available from http://www.rcog.org.uk/womens-health/patient-information/medical-terms-explained.

23.

US Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1–19.

24.

Rabe-Hesketh

, Skrondal

, Pickles

Reliable estimation of generalised linear mixed models using adaptive quadrature. Stata J 2002; 2: 1–21.

25.

Mayaux

M.J.

, Teglas

J.P.

, Blanche

, the French Pediatric HIV Infection Study Group. Characteristics of HIV-infected women who do not receive preventive antiretroviral therapy in the French Perinatal Cohort. J Acquir Immune Defic Syndr 2003; 34: 338–343.

26.

Vandermaelen

, Barlow

, Manigart

Optimal management of HIV-infected women during pregnancy and delivery: an audit of compliance with recommendations. J Womens Health (Larchmt) 2009; 18: 1881–1887.

27.

Kuhn

, Steketee

R.W.

, Weedon

Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. Perinatal AIDS Collaborative Transmission Study. J Infect Dis 1999; 179: 52–58.

28.

European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13: 1377–1385.

29.

European Collaborative Study, the Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913–2920.

30.

Machado

E.S.

, Hofer

C.B.

, Costa

T.T.

Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85: 82–87.

31.

Grosch-Woerner

, Puch

, Maier

R.F.

Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008; 9: 6–13.

32.

HIV/AIDS Programme WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in their infants: Recommendations for a public health approach. 2010 version. Geneva, Switzerland: World Health Organisation; 2010.

33.

Giraudon

, Forde

, Maguire

, Arnold

, Permalloo

Antenatal screening and prevalence of infection: surveillance in London, 2000–2007. Eurosurveillance 2009; 14: 8–12.

34.

Department of Health UK. Definitions of health literacy. (Updated 10 August 2009. Accessed 10 March 2010.) Available from http://wwwdhgovuk/en/Publichealth/Healthimprovement/Healthliteracy/DH_095381.

35.

Turner

B.J.

, Cunningham

W.E.

, Duan

Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med 2000; 160: 2614–2622.

36.

Samet

J.H.

, Freedberg

K.A.

, Stein

M.D.

Trillion virion delay; time from testing positive for HIV to presentation for primary care. Arch Intern Med 1998; 158: 734–740.

37.

Torian

L.V.

, Wiewel

E.W.

, Liu

K.L.

, Sackoff

J.E.

, Frieden

T.R.

Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med 2008; 168: 1181–1187.

38.

Peters

, Liu

K.L.

, Dominguez

Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996–2000, Pediatric Spectrum of HIV Disease Cohort. Pediatrics 2003; 111: 1186–1191.

39.

Cohen

M.H.

, Cook

J.A.

, Grey

Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health 2004; 94: 1147–1151.

40.

Gebo

K.A.

, Fleishman

J.A.

, Conviser

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38: 96–103.

41.

Minozzi

, Amato

, Vecchi

, Davoli

Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008; 16: CD006318.